The HBV Forum 8 was held in London, UK on June 21, 2022 

Materials

Agenda

Participant List

 

Presentations

Welcoming Remarks

Veronica Miller, Forum for Collaborative Research

Session I: Working Group and Regulatory Updates

CAM Nomenclature Working Group Update

Harry L. A. Janssen, Eramus Medical Center

Immune Monitoring Working Group Update

Adam Gehring, Toronto Centre for Liver Disease

Regulatory Updates

Virginia Sheikh, FDA

HBV Forum Webinar Series Recap

Veronica Miller, Forum for Collaborative Research

Session II: "Stopping Finite Treatment" Paper Presentation

Stopping Finite Treatment Working Group Update

Marion Peters, University of California, San Francisco

Kosh Agarwal, King's College London

Session III: Launch of HDV Co-Infection Working Group

Launch of HDV Co-infection Working Group

Norah Terrault, University of Southern California

Heiner Wedemeyer, Medizinische Hochschule Hannover 

EMA Perspective on Optimal Trial Design for Phase 3 Trials of Novel Therapies for Chronic Hepatitis D

Stephanie Buchholz, Clinical Assessor Antivirals

Session IV: The Role of Biomarkers in Drug Development

S Antigen Isoform and Immune Complexes Dynamics

Gavin Cloherty, Abbott

HBcrAg and HBV RNA

Man-Fung Yuen, The University of Hong Kong